(SWOG S1203) A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) Versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Description: 

(Chemotherapy): To compare event-free survival (EFS) between patients with AML who receive standard 7+3 or idarubicin and high-dose cytarabine (IA) to patients who receive IA + vorinostat.(Transplant): To determine whether it is possible to get 60% or more of adults with high-risk AML (by cytogenetics) in first complete.

Study Number: 

NCG 245013

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01802333

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.